ArticleCureus2025
Clinical and Therapeutic Challenges in Aggressive Diffuse Large B-Cell Lymphoma of Immune-Privileged Sites: A Case Report of Orbital and Cervical Involvement in an End-Stage Renal Disease (ESRD) Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. We report a rare and diagnostically complex case of aggressive DLBCL manifesting in immune-privileged and atypical extranodal sites of the head and neck, including bilateral retrobulbar regions, optic nerves, zygomatic muscle, cervical soft tissues, and paraspinal musculature, in a 70-year-old male patient with multiple comorbidities including end-stage renal disease (ESRD) and prior cerebrovascular accident. The patient presented with rapidly progressive bilateral proptosis and systemic signs of sepsis. Diagnostic imaging, constrained by renal insufficiency, revealed multifocal soft tissue masses without intracranial involvement. Histopathology and immunohistochemistry confirmed nongerminal center subtype DLBCL (CD20+, BCL2+, MUM1+, MYC-, CD3-, CD7-). Bone marrow analysis excluded systemic leukemic-phase disease. Due to the patient's frailty and organ dysfunction, standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy was contraindicated; a modified immunochemotherapy with corticosteroids and rituximab was initiated, yielding a partial reduction in tumor size. Despite initial improvement, the patient succumbed to complications of multiorgan failure. This case highlights the clinical and therapeutic challenges in diagnosing and managing extranodal DLBCL in elderly, immunocompromised patients, especially when the disease involves immune-privileged sites and standard diagnostic tools are limited.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.